FollowTheFilings

🚨 $LLY FOUNDAYO: DISASTROUS PHASE 3 RESULTS IN JAPAN. The numbers are brutal. Eli Lilly’s oral obesity drug is delivering roughly HALF the weight loss of $NVO’s oral semaglutide, while suffering massive treatment discontinuation at its highest dose. ATTAIN-J Phase 3 — 72 weeks, 36 mg: 🔴 Just 7.9% weight loss (treatment-regimen estimand). 🔴 33.3% discontinued treatment at the highest dose. ONE IN THREE patients! Versus 15% on placebo. 🔴 Only 58.8% achieved even 5% weight loss. 🔴 Increasing the dose from 12 mg to 36 mg actually produced WORSE average results: 8.7% vs 7.9%. Now compare that with $NVO’s oral semaglutide 50 mg in the East Asian OASIS 2 trial: 🟢 14.3% weight loss at 68 weeks. 🟢 84.3% achieved at least 5% weight loss. 🟢 Just 4.5% discontinued because of adverse events. These are separate trials, not a head-to-head comparison, but the contrast is extraordinary. Foundayo delivered only 55% of semaglutide’s reported weight-loss efficacy, despite using its highest tested dose. And the discontinuation numbers raise serious questions about long-term tolerability and commercial persistence. This is supposed to be Lilly’s next global oral obesity blockbuster? If these results are replicated across international populations, the commercial implications could be enormous. The narrative that Lilly will dominate the global oral obesity market deserves serious reconsideration. A major competitive warning for $LLY. A potentially significant opportunity for $NVO. $NVO $LLY $VKTX

Everyone should be paying attention to semaglutide. 2026 studies found 12% longer median lifespan in female mice and slower epigenetic aging markers in humans. I feel the difference myself: I go running, don't drink alcohol, and my liver-area pain has disappeared. Semaglutide could be much more than a weight-loss drug. $NVO

The fundamental mistake in AI revenue projections is assuming that one side of the economic equation remains unchanged. AI eliminates jobs, salaries, operating costs and entire layers of intermediate demand. At the same time, automated companies can slash prices because they no longer need the same human resources. And people claim lower prices will create more demand. From whom? Who will have the income to buy those products? Lower prices do not create purchasing power. If AI replaces millions of workers, it also destroys the income that supports consumption. The result could be massive deflation, unemployment and collapsing nominal revenues. You cannot project trillions in future AI revenues using today's economic structure when the technology itself is supposed to dismantle that structure. The more successful AI becomes at eliminating costs, the more it risks destroying the very revenue base needed to justify its valuations.

🚨 $NVO — THE MARKET IS MISSING THE BIGGER PICTURE. This is a marathon, not a sprint. And Symphony Health's prescription data suggests we may be witnessing the birth of an entirely new pharmaceutical paradigm. Let's look at the numbers. 📊 SYMPHONY HEALTH — U.S. WEEKLY PRESCRIPTIONS Wegovy oral: • Week 27: 119,347 • Week 35: 144,431 • Week 42: 217,050 That's +81.9% in just 15 weeks! Meanwhile, $LLY's Foundayo recorded only 29,155 prescriptions in week 42. Wegovy oral is outselling Foundayo by 7.4 to 1 in Symphony's prescription dataset. And these figures exclude significant online pharmacy and telehealth channels. 💰 NOW LET'S PROJECT 2027. Novo already reported DKK 3.22B in Wegovy oral sales in Q2 2026, before meaningful international expansion. Using Symphony's U.S. prescription trajectory as our volume reference, my 2027 scenario assumes: • U.S. Wegovy oral revenue: $5.9B • International revenue: $2.96B (50% of U.S.) • Global Wegovy oral revenue: $8.86B At EUR/USD 1.09 and EUR/DKK 7.46, that represents approximately DKK 60.6B. Now consider Novo Nordisk's entire business. 2025 actual revenue: DKK 309.1B. Assume every other business grows just 5% cumulatively by 2027, with oral Wegovy providing incremental revenue. 2027 projected total: DKK 385.2B. 🚀 THAT'S +24.6% REVENUE GROWTH IN DKK VERSUS 2025. And this scenario doesn't require explosive growth from Ozempic, injectable Wegovy or the rest of Novo's portfolio. It does require continued prescription growth, international adoption and successful monetization. This is my scenario, not company guidance. This is why I'm looking beyond quarterly market-share headlines. We may be witnessing the beginning of a completely new paradigm in obesity treatment, with extraordinary commercial potential. Nobody knows how big this market can ultimately become. The marathon has barely begun. $NVO $LLY

The growing nervousness among $LLY bulls is becoming increasingly obvious. Now they're openly complaining about LillyDirect, prescription delays, customer acquisition friction and lost sales opportunities. And yet the market continues to value Lilly as if its competitive dominance were virtually guaranteed. Look at the valuations: $LLY: $1.14 TRILLION market cap. ~33x forward earnings. $NVO: $172 BILLION market cap. ~12x forward earnings. Almost THREE TIMES the earnings multiple! Meanwhile, Novo already has oral Wegovy, Wegovy HD, CagriSema approaching a regulatory decision, and an expanding next-generation pipeline. The problem isn't that Lilly is a bad company. It's that its valuation leaves very little room for competitive surprises. And Novo is delivering precisely those surprises. This valuation gap is becoming increasingly difficult to justify. The more defensive Lilly bulls become, the more obvious the risk of a major market repricing. $NVO $LLY

These numbers deserve MUCH more attention. CagriSema 2.4/2.4 mg vs Zepbound 15 mg in WOMEN: Premenopausal: CagriSema 26.7% vs Zepbound 26% Perimenopausal: CagriSema 24.8% vs Zepbound 23% Postmenopausal: CagriSema 23.1% vs Zepbound 23% Overall female analyses: CagriSema 25% vs Zepbound approximately 25%. Different clinical trials, not a head-to-head comparison, but the numerical results are remarkable. And remember: CagriSema achieves these results with just 2.4 mg of semaglutide plus 2.4 mg of cagrilintide. You don't have to prove superiority over Lilly to recognize the enormous commercial opportunity here. The real question is how much market expansion Novo can unlock with effective pricing and sufficient manufacturing capacity. $NVO $LLY

Here's what I think $NVO bears are completely missing. Novo will launch CagriSema at $150/month. Think about the implications. Wegovy HD requires 7.2 mg of semaglutide weekly to deliver 20.7% weight loss. CagriSema combines just 2.4 mg of semaglutide with 2.4 mg of cagrilintide and delivered 22.7% overall weight loss, reaching 25% in women. One-third of the semaglutide dose. A second mechanism of action. Exceptional clinical efficacy. The manufacturing economics deserve far more attention than they are getting. At $150/month, the addressable market could explode. Millions of patients who have a prescription but cannot afford treatment could suddenly enter the market. That is how you transform an entire industry: not by fighting endlessly over existing customers, but by making treatment accessible to millions more. And Wall Street is still debating whether CagriSema can steal a few patients from Zepbound. They're looking at the wrong opportunity. $NVO $LLY

$NVO — CagriSema 2.4/2.4 mg at $125/month after FDA approval could completely transform the obesity market. And it would fit Novo's announced 2027 price reduction strategy. Wall Street is looking at this market COMPLETELY WRONG. REDEFINE 4: CagriSema: 23% weight loss. Zepbound 15 mg: 25.5%. Zepbound's regular self-pay price: $699/month. At $125, CagriSema will be 82% cheaper for just 2.5 percentage points less weight loss. But THE REAL STORY ISN'T EFFICACY ANYMORE. IT'S PRICE, VOLUME AND INDUSTRIAL EFFICIENCY. According to IQVIA, only 35 out of 100 new obesity prescriptions in the commercially insured market are actually filled. The patients exist. The prescriptions exist. But affordability and insurance restrictions prevent millions of treatments from starting. Imagine recovering those patients with a $125/month treatment. Now consider the manufacturing advantage. CagriSema 2.4/2.4 uses THREE TIMES LESS semaglutide than Wegovy HD 7.2 mg. And Novo has already demonstrated 21% weight loss with CagriSema 1/1 mg in another trial. Just ONE milligram of semaglutide weekly! NOW THINK ABOUT GENERICS. This is what analysts seem to be completely missing in their 4-year valuation models. They assume semaglutide patent expiration means inevitable price destruction and declining $NVO profitability. But generic manufacturers cannot simply copy CagriSema's patented combination. To compete with its efficacy using semaglutide alone, they could need substantially higher doses, enormous API production capacity and considerable industrial investment. Meanwhile, Novo estimates US patent protection for CagriSema until 2039. GENERIC COMPETITION IS NOT JUST ABOUT PATENT EXPIRATION. IT'S ABOUT MANUFACTURING CAPACITY, COST PER PATIENT AND PRODUCT DIFFERENTIATION. What if Novo can treat several times more patients with the same semaglutide capacity while cutting prices dramatically? What if its next growth phase comes from converting millions of abandoned prescriptions into actual treatments? And what if a future low-cost CagriSema 1/1 mg makes this advantage even greater? Analysts are valuing Novo four years ahead while obsessing over a 2.5-point efficacy difference and the semaglutide patent cliff. They're overlooking the possibility that Novo could transform its entire business model before that cliff arrives. Lower prices. Millions more patients. Greater manufacturing efficiency. A differentiated product protected well beyond semaglutide's expected patent expiration. CAGRiSEMA COULD BE NOVO'S DEFENCE AGAINST GENERICS AND ITS BIGGEST GROWTH OPPORTUNITY. THE NEXT OBESITY MARKET BATTLE WILL BE WON THROUGH VOLUME, ACCESS AND INDUSTRIAL SCALE. Not by another 2% of weight loss. $NVO $LLY

Wall Street is missing the real CagriSema story. And I believe it could completely change the investment thesis for $NVO. Everyone is obsessed with maximum weight loss percentages. Who gets 23%, 25% or 27%? Wrong question. The real question is: HOW MUCH semaglutide do you need to achieve approximately 20% weight loss? Look at Novo Nordisk's own clinical results: CagriSema 1 mg/1 mg: 21% weight loss. Wegovy HD 7.2 mg: 20.7% weight loss. Different trials, different durations, not a head-to-head comparison. But the difference in semaglutide consumption is extraordinary. CagriSema delivers approximately 20% weight loss using just ONE milligram of semaglutide, combined with 1 mg of cagrilintide. Now think about manufacturing economics. To supply 10 million patients for one year at those weekly doses: CagriSema requires 520 kg of semaglutide. Wegovy HD requires 3,744 kg. At 100 million patients: CagriSema: 5.2 metric tonnes. Wegovy HD: 37.44 metric tonnes. That is a 7.2x difference in semaglutide API requirements. And THIS is where the generic competition story becomes very interesting. Analysts keep discussing semaglutide patent expiration as if generic manufacturers could simply enter the market, slash prices and destroy Novo's economics. But who is going to manufacture the quantities required to serve tens of millions of patients? A generic manufacturer attempting to replicate approximately 20% weight loss using high-dose semaglutide alone faces vastly greater semaglutide production requirements than Novo would with CagriSema 1/1 mg. That means manufacturing capacity, capital investment, production costs and supply-chain execution. CagriSema also requires cagrilintide, so the total manufacturing cost advantage is not yet established. But the semaglutide capacity advantage is impossible to ignore. And there is another critical point. Novo estimates US semaglutide patent expiration in 2032. CagriSema's estimated patent protection extends to 2037. A differentiated, patent-protected combination that potentially allows Novo to treat dramatically more patients using the same semaglutide production capacity. Think about it. The obesity market is still in its infancy. Hundreds of millions of people worldwide could eventually need treatment, and many will require long-term maintenance. The winner will not necessarily be the company achieving the highest percentage of weight loss in a clinical trial. It could be the company capable of delivering clinically meaningful weight loss to the greatest number of patients at the lowest sustainable cost, with a defensible intellectual-property position. In my view, CagriSema could be Novo Nordisk's lifeline. Not because it wins every maximum-dose efficacy comparison. Because it potentially changes the entire economics of semaglutide treatment and creates a formidable industrial barrier against generic competition. Wall Street is still treating CagriSema as a weight-loss percentage story. I think it is a manufacturing scale, API efficiency and patent protection story. And that distinction could be worth billions. $NVO $LLY

Everyone is missing the real $NVO story. CagriSema achieved 21% weight loss using just 1 mg of semaglutide + 1 mg cagrilintide. Wegovy HD achieved 20.7% using 7.2 mg of semaglutide. Different trials, but a staggering difference in semaglutide requirements. Now think about generics. Semaglutide patents extend to 2031–2032 in major markets. Canada already shows that patent expiry does not translate into immediate generic dominance. Even when generics arrive, competing with this combination using semaglutide alone could require dramatically more active ingredient. And Novo has estimated patent protection for CagriSema until 2037. Think manufacturing economics, lifelong maintenance and the hundreds of millions of patients still waiting for treatment. This is much bigger than another 1–2% of weight loss.

The $LLY bulls are seriously underestimating what $NVO has just demonstrated with CagriSema. REIMAGINE 5, patients with type 2 diabetes, 60 weeks: CagriSema (1 mg semaglutide + 1 mg cagrilintide): 12.4% weight loss. Tirzepatide 5 mg: 9.1% weight loss. That's 36% GREATER weight loss, with non-inferior glucose control (HbA1c reduction of 1.71% vs 1.67%). Think about that. Just 1 mg of semaglutide, combined with 1 mg of cagrilintide, significantly outperforms 5 mg of tirzepatide in a head-to-head phase 3 trial. And REDEFINE 9 delivered 21% weight loss in obesity with that same 1/1 mg combination. This is not simply another version of Wegovy HD. It's evidence of how powerful GLP-1 + amylin biology can be. The comparison is against tirzepatide 5 mg, not its maximum 15 mg dose. But the result is undeniable. Those calling CagriSema redundant are missing the bigger picture: Novo may be unlocking substantial efficacy without needing massive doses of semaglutide. And that could change the competitive landscape completely. $NVO $LLY

Investment-risk thesis: Retatrutide’s commercial and valuation outlook could be vulnerable to safety-related reputational damage and intensifying competitive pressure. Two deaths have been reported to the FDA in connection with products sold as retatrutide. Although causality has not been established, the reports could increase regulatory scrutiny and undermine investor and patient confidence if further adverse events emerge. The risk is amplified by Eli Lilly’s substantial valuation premium. Novo Nordisk already has UBT251, which delivered 19.7% weight loss over 24 weeks, highlighting the potential for credible competition in the next generation of obesity treatments. The measured conclusion is that the reported deaths do not, by themselves, establish a product-specific safety signal. However, if retatrutide’s clinical or reputational momentum weakens while competitors continue to demonstrate strong efficacy, Eli Lilly’s premium valuation could compress and create meaningful downside for $LLY.

🚨 $LLY RETATRUTIDE: TWO FATAL CARDIAC ARREST REPORTS RECEIVED BY THE FDA. PATIENTS AGED 41 AND 49. And the second case is particularly disturbing. According to the FDA report obtained by CBS News, a LICENSED NURSE allegedly convinced the 49-year-old patient to purchase retatrutide, supplied the link, sold her the vials AND provided dosing instructions. The patient subsequently suffered severe dehydration, malnutrition and cardiac arrest. The first case involved a 41-year-old woman with a dangerously rapid heartbeat before cardiac arrest. Now consider what retatrutide trials have already shown: • Dose-dependent increases in heart rate. • Hypotension at higher doses. • Neurological sensory disturbances. These are not proof that retatrutide caused either death. The reports and products remain unverified. But the clinical overlap demands investigation. TWO deaths reported to the FDA. Both patients under 50. Both involving cardiac arrest. And investors are treating FDA approval as a certainty? The regulator needs answers about product identity, dosing, dehydration and cardiovascular mechanisms before these reports can be properly assessed. A 30% weight-loss headline does not settle the benefit-risk equation. $LLY